EVAXION BIOTECH A/S (EVAX)
US29970R1059 - ADR
EVAXION BIOTECH A/S
NASDAQ:EVAX (11/28/2023, 7:00:44 PM)
After market: 0.79 0 (-0.27%)0.7921
-0.02 (-2.21%)
Company Profile
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Company Info
EVAXION BIOTECH A/S
Bredgade 34E, Copenhagen K
COPENHAGEN 1260
CEO: Lars Staal Webner
Employees: 63
Website: https://www.evaxion-biotech.com/
EVAX News
a day ago - Evaxion BiotechEvaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine ConceptProof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a...
Evaxion présente aujourd’hui un nouveau modèle d’IA conçu pour prédire les réponses des patients à une immunothérapie anticancéreuse standard.Le modèle a...
Evaxion präsentiert heute ein neuartiges KI-Modell zur Vorhersage des Ansprechens von Patienten auf eine Standard-KrebsimmuntherapieDas Modell zeigt ein...
14 days ago - Evaxion BiotechEvaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer ImmunotherapyEvaxion today presents a novel AI model designed to predict patient responses to standard-of-care cancer immunotherapyThe model demonstrates promising...
EVAX Twits
Here you can normally see the latest stock twits on EVAX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
